Whilst the ophthalmology research community is incredibly innovative and has brought many new therapies to the market over the past few years, there remain multiple unmet needs for patients with ophthalmic diseases. Our goal is to address some of these with our portfolio of promising and exciting therapeutic candidates.
As described further in our Products pages, Kiora is developing KIO-101 for Dry Eye Disease, KIO-201 for Ocular Wound Healing and KIO-301 for inherited and age-related retinal degenerative diseases, including Retinitis Pigmentosa.
January 10 – 13, 2022
Kiora Pharmaceuticals, Inc.
View the Presentation